240 related articles for article (PubMed ID: 21196550)
1. Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study.
Jensen CD; Steval A; Partington PF; Reed MR; Muller SD
J Bone Joint Surg Br; 2011 Jan; 93(1):91-5. PubMed ID: 21196550
[TBL] [Abstract][Full Text] [Related]
2. A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis.
Chahal GS; Saithna A; Brewster M; Gilbody J; Lever S; Khan WS; Foguet P
Ortop Traumatol Rehabil; 2013; 15(2):125-9. PubMed ID: 23652532
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
[TBL] [Abstract][Full Text] [Related]
4. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty.
Jameson SS; Rymaszewska M; Hui AC; James P; Serrano-Pedraza I; Muller SD
J Bone Joint Surg Am; 2012 Sep; 94(17):1554-8. PubMed ID: 22832942
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Fisher WD; Eriksson BI; Bauer KA; Borris L; Dahl OE; Gent M; Haas S; Homering M; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
Thromb Haemost; 2007 Jun; 97(6):931-7. PubMed ID: 17549294
[TBL] [Abstract][Full Text] [Related]
6. The use of rivaroxaban for chemical thromboprophylaxis following total knee replacement.
Rath NK; Goodson MW; White SP; Forster MC
Knee; 2013 Dec; 20(6):397-400. PubMed ID: 23566737
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.
Prescrire Int; 2009 Aug; 18(102):151-3. PubMed ID: 19743567
[TBL] [Abstract][Full Text] [Related]
8. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
Kakkar AK; Brenner B; Dahl OE; Eriksson BI; Mouret P; Muntz J; Soglian AG; Pap AF; Misselwitz F; Haas S;
Lancet; 2008 Jul; 372(9632):31-9. PubMed ID: 18582928
[TBL] [Abstract][Full Text] [Related]
9. Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: the Safe, Simple Transitions (SST) study.
Mills RM; Berkowitz RD; Damaraju CV; Jennings LK; Wildgoose P
Thromb Res; 2012 Nov; 130(5):709-15. PubMed ID: 22857800
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
11. [Case-control study on three antithrombotic agents for the prevention of venous thromboembolism after unilateral total knee arthroplasty].
Miao SG; Zhang XG; Lu JH; Yang Y; Lu N
Zhongguo Gu Shang; 2015 Oct; 28(10):893-6. PubMed ID: 26727779
[TBL] [Abstract][Full Text] [Related]
12. [Prophylaxis of thrombembolic diseases with rivaroxaban].
Gassanov N; Caglayan E; Erdmann E; Er F
Dtsch Med Wochenschr; 2010 Nov; 135(44):2189-92. PubMed ID: 20979005
[No Abstract] [Full Text] [Related]
13. Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data.
Kwong LM
Vasc Health Risk Manag; 2011; 7():461-6. PubMed ID: 21822393
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Duggan ST
Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
[TBL] [Abstract][Full Text] [Related]
15. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
Turpie AG; Haas S; Kreutz R; Mantovani LG; Pattanayak CW; Holberg G; Jamal W; Schmidt A; van Eickels M; Lassen MR
Thromb Haemost; 2014 Jan; 111(1):94-102. PubMed ID: 24154549
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study.
Lazo-Langner A; Fleet JL; McArthur E; Garg AX
J Thromb Haemost; 2014 Oct; 12(10):1626-35. PubMed ID: 25069387
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
19. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
Lassen MR; Gent M; Kakkar AK; Eriksson BI; Homering M; Berkowitz SD; Turpie AG
J Bone Joint Surg Br; 2012 Nov; 94(11):1573-8. PubMed ID: 23109641
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban to prevent pulmonary embolism after hip or knee replacement.
Cios D; Fanikos J
Circulation; 2012 Apr; 125(14):e542-4. PubMed ID: 22492951
[No Abstract] [Full Text] [Related]
[Next] [New Search]
